Compare Novo Nordisk A/S (NVO) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs SkyWest Inc — how do they compare? Novo Nordisk A/S trades at $44.71 (market cap $200.69B), while SkyWest Inc trades at $96.26 (market cap $3.69B). The key difference: Novo Nordisk A/S is far larger — about 54.4× SkyWest Inc's market cap, and Novo Nordisk A/S pays a 3.98% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals.
| NVO | SKYW | |
|---|---|---|
Market Cap | $200.69B | $3.69B |
Sector | Health | Technology |
52-Week High | $63.98 | $115.94 |
52-Week Low | $35.29 | $78.40 |
Enterprise Value | $215.49B | $5.47B |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
SkyWest (SKYW) trades at $94.98, down 4.12% on the day, amid a bearish technical signal. The stock shows mixed earnings performance with a recent Q2 2026 miss but a Q1 beat, while maintaining solid profitability with a net margin of 9.78% and ROE of 15.34%. Valuation metrics appear attractive with a P/E of 9.44 and P/S of 0.92, below industry averages. Recent news highlights institutional interest and fleet expansion as growth drivers.
The outlook is cautiously optimistic given strong analyst support—56% buy ratings with a $112 consensus target—and robust cash flow trends. Key risks include earnings volatility, cost pressures from maintenance and fuel, and insider selling. The stock presents a value opportunity if operational execution improves, but investors should monitor quarterly results for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
